Page 182 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer

Chapter 9
180
Table 1 Data characteristics General information
89Zr-antiCD20
89Zr-antiEGFR
89Zr-antiPSMA
89Zr-antiHER2
mAb
Obinutuzumab Humanized IgG1
Cetuximab Chimeric IgG1
Hu-J591 Humanized IgG1
Trastuzumab Humanized IgG1
Type
IgG subclass
Target expression(20) • - Kidney
Absent Absent Absent Present
Absent Present Absent Absent
Present Present Absent Absent*
Absent Present Present Absent
• - Liver • - Lung • - Spleen
Study design
Center
Amsterdam UMC(n=4) CHU Lille(n=5)
Amsterdam UMC
MSKCC
MSKCC
Patient category
Number of patients Injected activity/mAb dose
Non-Hodgkin lymphoma 9
Colo-rectal carcinoma
Prostate cancer 10
Gastric cancer 10
Administration**
PET scan time points Blood sample***
Blood sampling timepoints
predose
predose
1hr,72h,144h p.i. plasma 1-2h,24h,48h,72h,144h
co-injection
co-injection
Reference
Jauw, et al.(16)
Menke, et al.(17)
Pandit-Taskar, et al.(18)
O’Donoghue,et al.(19)
37MBq/10 mg
1000mg unlabeled mAb
37MBq/10mg
500mg/m2 unlabeled mAb
185MBq/1.7mg
total mass of 25mg mAb
185MBq/3mg
total mass of 50mg mAb
1 hr,72h,144h p.i.
2-4h,24h,48-120h,144-168h p.i.
4h,24h,48-96h,120-192h p.i.
plasma
serum
serum
5,30,60,120min,24h****, 72h,144h p.i.
5,30,60,120-240min,24h,48- 120h, 144-168h p.i.
5,15,30,60min,2h,24h,48-96h, 120- 192h p.i.
7
*Expression of PSMA in the spleen has been reported(24)
**Administration: predose = 89Zr-mAb within 2 hours after administration of unlabeled mAb.
co-injection = unlabeled mAb infused intravenously over 5min followed immediately by a 1min infusion of the radiolabeled mAb.
***Blood samples consisted of plasma or serum samples; assuming no practical difference between these assays for our purposes, since mAb binding does not occur to coagulation factors (the difference between plasma and serum).
****Blood samples obtained at 24h p.i. at CHU Lille(n=5), no 24h sample obtained at Amsterdam UMC